Adamas Pharmaceuticals to Present at the 25th Annual Credit Suisse Healthcare Conference
October 24 2016 - 4:05PM
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced
that Gregory T. Went, Ph.D., Chairman and Chief Executive
Officer of Adamas, will present at the Credit Suisse Healthcare
Conference in Scottsdale, Arizona on Monday, November 7,
2016 at 8:00 a.m. Mountain Time.
The presentation will be webcast live from the investor
relations section of the Adamas website
at http://ir.adamaspharma.com/events.cfm and available
for approximately two weeks.
About Adamas Pharmaceuticals Adamas
Pharmaceuticals, Inc. is driven to improve the lives of those
affected by chronic disorders of the central nervous system.
The company seeks to achieve this by modifying the pharmacokinetic
profiles of approved drugs to create novel therapeutics for use
alone and in fixed-dose combination products. Adamas is
currently developing ADS-5102, its lead wholly-owned product
candidate, for the treatment of levodopa-induced dyskinesia
associated with Parkinson's disease and for the treatment of major
symptoms associated with multiple sclerosis in patients with
walking impairment. The company is also evaluating ADS-4101,
a modified-release version of an FDA-approved single-agent compound
for the treatment of epilepsy. In addition, under a license
agreement with Forest Laboratories Holdings Limited, an indirect
wholly-owned subsidiary of Allergan plc., the company is eligible
to receive royalties from Forest on sales of Namenda XR® and
Namzaric™ beginning in June of 2018 and May of 2020,
respectively. For more information, please visit
www.adamaspharma.com.
Namzaric™ is a trademark of Merz Pharma GmbH & Co.
KGaA.Namenda XR® is a registered trademark of Merz Pharma GmbH
& Co. KGaA.
Contact:
Martin Forrest
VP Corporate Communications and Investor Relations
510-944-1112
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Apr 2023 to Apr 2024